Form D · Pharmaceuticals

CoMentis Inc

South San Francisco, CA · CIK 0001412391

Offering snapshot reported Mar 18, 2016 · SEC filing

Reported sold
$4.5M
Offering amount: $12M
Investors reported
2
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 2, 2016
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 18, 2016Initial$4,500,000No comparison2SEC filing
May 16, 2008PaperNot reportedNo comparisonNot reportedSEC filing
Oct 29, 2007PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity, Other
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$50K
Form D file number
021-259573
Offering of Series E Preferred Stock ("Series E") and the underlying shares of Common Stock issuable upon conversion of Series E.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Piper Jaffray & Co.665

Source: Form D, filed Mar 18, 2016. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Michael Detke, Md, Ph D Executive
Dennis Henner, Ph D Director
John L. Higgins Director
Daniel Hunt Executive
Terence Kelly, Ph D Director, Executive
Robert G. Mc Neil, Ph D Director
Fred Middleton Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
400 Oyster Point Blvd., Suite 226
South San Francisco, CA, 94080